Last reviewed · How we verify

Pro Top & Mediking Company Limited — Portfolio Competitive Intelligence Brief

Pro Top & Mediking Company Limited pipeline: 1 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Trabeculectomy with MMC Trabeculectomy with MMC marketed Ophthalmology
MMC in glaucoma filtering surgery MMC in glaucoma filtering surgery phase 3 Antiproliferative agent / Antimetabolite DNA (cross-linking agent) Ophthalmology
MMC in Trabeculectomy MMC in Trabeculectomy phase 3 Alkylating agent / Antimetabolite DNA cross-linking agent Ophthalmology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Pro Top & Mediking Company Limited:

Cite this brief

Drug Landscape (2026). Pro Top & Mediking Company Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pro-top-mediking-company-limited. Accessed 2026-05-18.

Related